Disclosed are P. gingivalis antibodies raised against a chimeric or fusion protein, wherein the chimeric or fusion protein comprises a first peptide joined directly or through a linker to a second peptide or polypeptide, wherein (A) the first peptide comprises a region of a P. gingivalis trypsin-like enzyme and (B) the second peptide or polypeptide comprises an adhesin domain of P. gingivalis.

The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.

The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.

Described are compositions and methods for treating inflammatory bowel diseases in a subject in need thereof. In certain aspects, the disclosure provides methods of treating a subject diagnosed with Irritable Bowel Disease (IBD), the method comprising administering to the subject an agent to reduce the number or pathogenic effects of a B. fragilis strain, wherein the subject is diagnosed with IBD by detecting the presence of the B. fragilis strain or a B. fragilis toxin in a biological sample of the patient.

Disclosed herein are methods of diagnosing Rheumatoid arthritis in a subject comprising determining whether the subject is immunologically reactive with P. copri or a portion thereof. In one aspect of the invention the immunological reactivity of the subject to one or more protein of P. copri or polypeptide fragments thereof such as protein Pc-p27 or polypeptide fragments thereof, as compared to an appropriate control, indicates the subject has rheumatoid arthritis. Examples of specific assays, compositions, and kits for use with the methods are also disclosed.

The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.

Disclosed herein are methods of diagnosing Rheumatoid arthritis in a subject comprising determining whether the subject is immunologically reactive with P. copri or a portion thereof. In one aspect of the invention the immunological reactivity of the subject to one or more protein of P. copri or polypeptide fragments thereof such as protein Pc-p27 or polypeptide fragments thereof, as compared to an appropriate control, indicates the subject has rheumatoid arthritis. Examples of specific assays, compositions, and kits for use with the methods are also disclosed.

The invention relates to generation and use of cellular and humoral responses for the prevention and treatment of P. gingivalis related conditions and diseases.

Disclosed herein are methods of diagnosing Rheumatoid arthritis in a subject comprising determining whether the subject is immunologically reactive with P. copri or a portion thereof. In one aspect of the invention the immunological reactivity of the subject to one or more protein of P. copri or polypeptide fragments thereof such as protein Pc-p27 or polypeptide fragments thereof, as compared to an appropriate control, indicates the subject has rheumatoid arthritis. Examples of specific assays and kits for use with the methods are also disclosed.

The present invention pertains to microorganisms of the species Bacteroides xylanisolvens expressing a core-1 antigen on their surface. These microorganisms are in particular useful for the prophylaxis and treatment of core-1 positive diseases and are particularly characterized by a stable, homogenous high core-1 expression. Also provided are pharmaceutical compositions which comprise respective core-1 positive microorganisms or fractions thereof.